Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
"City air pollution as deadly as a packet of cigarettes a day for 29 years"
City air pollution as deadly as a packet of cigarettes a day for 29 years
Researchers found a particular association between ground level ozone and emphysema.
bit.ly
We support the work of the @Go2Foundation in the national call for #LungCancer research, early detection, and access to high-quality care. #SaveHerLungs #PatientsFirst #ItsPersonal
Thursday August 1st is #WorldLungCancerDay: CELEBRATE-COMMEMORATE-SUPPORT the global community affected by Lung Cancer! Now in its 8th year, #WLCD is a powerful grassroots initiative started by survivor Betsy Thompson. Join us as we rock Twitter with LC Awareness! #lcsm #hcsm
"With early detection, the 5-year survival rate for #lungcancer triples to 56%. Confirming the malignancy of a nodule with EarlyCDT Lung can lead to earlier intervention and better results." #detectcancerearly
Mike Fisher PhD on Twitter
“Great to see EarlyCDT-Lung for detection of #lungcancer being promoted by Quirónsalud in Spain. @SABARTECH SL https://t.co/L2p04luZvF”
twitter.com
$ONC Oncimmune Holdings hails latest Spain deal for Lung cancer detection device via @proactive_UK @OncimmuneECDT #ONC #brighterir #AndrewScottTV #CapitalNetwork1
Oncimmune Holdings hails latest Spain deal for Lung cancer detection device
Local distributor Sabartech has inked an agreement with Vithas Group, which operates 48 hospitals and medical centres
tinyurl.com
Further expansion in Spain for our EarlyCDT® Lung as a screening test #lungcancer #detectcancerearly
Biodesix Inc. will extend the company's blood-based lung cancer diagnostic portfolio with the acquisition of Oncimmune and its De Soto laboratory. Biodesix COO Scott Hutton discusses the future of the local laboratory.
Only two days to go until the Proactive One2One Forum where @OncimmuneECDT, @Clinigen, @cellohealth & @MaxCyte_info will all be presenting. Details and registration below:
Proactive Investors Limited - Leading source of Financial News, Investor Forums, CEO Interviews, Financial Columnists, Stock Information
Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price.....
www.proactiveinvestors.co.uk
Gallery
